Epidemiology of Febrile Neutropenia Episodes with Gram-Negative Bacteria Infection in Patients Who Have Undergone Chemotherapy for Hematologic Malignancies: A Retrospective Study of 10 Years' Data from a Single Center

References

• Alp S, Akova M. Management of febrile neutropenia in the era of bacterial resistance. Ther Adv Infect Dis. 2013;1(1):37–43. doi:10.1177/204993611347561025165543
   PubMedGoogle Scholar
• Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. J Clin Oncol. 2018;36(14);Jco2017776211.
   Web of Science ®Google Scholar
• Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017;102(3):433–444. doi:10.3324/haematol.2016.15290028011902
   PubMed Web of Science ®Google Scholar
• Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27(suppl 5):v111–v8. doi:10.1093/annonc/mdw32527664247
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10):2258–2266. doi:10.1002/(ISSN)1097-014216575919
   PubMed Web of Science ®Google Scholar
• Gajdacs M, Burian K, Terhes G. Resistance levels and epidemiology of non-fermenting gram-negative bacteria in urinary tract infections of inpatients and outpatients (RENFUTI): a 10-year epidemiological snapshot. Antibiotics (Basel). 2019;8:3.
   Web of Science ®Google Scholar
• Gajdacs M, Urban E. Epidemiological trends and resistance associated with stenotrophomonas maltophilia bacteremia: a 10-year retrospective cohort study in a tertiary-care hospital in hungary. Diseases. 2019;7(2):41. doi:10.3390/diseases7020041
   PubMed Web of Science ®Google Scholar
• Gajdacs M. The continuing threat of methicillin-resistant staphylococcus aureus. Antibiotics (Basel). 2019;8:2.
   Web of Science ®Google Scholar
• Klastersky J, Ameye L, Maertens J, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents. 2007;30(Suppl 1):S51–S59. doi:10.1016/j.ijantimicag.2007.06.01217689933
   PubMed Web of Science ®Google Scholar
• Horita N, Shibata Y, Watanabe H, Namkoong H, Kaneko T. Comparison of antipseudomonal beta-lactams for febrile neutropenia empiric therapy: systematic review and network meta-analysis. Clin Microbiol Infect. 2017;23(10):723–729. doi:10.1016/j.cmi.2017.03.02428377312
   PubMed Web of Science ®Google Scholar
• Chen K, Wang Q, Pleasants RA, et al. Empiric treatment against invasive fungal diseases in febrile neutropenic patients: a systematic review and network meta-analysis. BMC Infect Dis. 2017;17(1):159. doi:10.1186/s12879-017-2263-628219330
   PubMed Web of Science ®Google Scholar
• Manji A, Lehrnbecher T, Dupuis LL, Beyene J, Sung L. A systematic review and meta-analysis of anti-pseudomonal penicillins and carbapenems in pediatric febrile neutropenia. Support Care Cancer. 2012;20(10):2295–2304. doi:10.1007/s00520-011-1333-322138849
   PubMed Web of Science ®Google Scholar
• Wang S, Zhao SY, Xiao SZ, et al. Antimicrobial resistance and molecular epidemiology of escherichia coli causing bloodstream infections in Three Hospitals in Shanghai, China. PLoS One. 2016;11(1):e0147740. doi:10.1371/journal.pone.014774026824702
   PubMed Web of Science ®Google Scholar
• Sun J, Xu Y, Yu Y, Ni Y. Accuracy of in vitro susceptibility tests for carbapenemase-producing Gram-negative bacteria. J Med Microbiol. 2015;64(6):620–622. doi:10.1099/jmm.0.00006725873580
   PubMed Web of Science ®Google Scholar
• Vinker-Shuster M, Stepensky P, Temper V, Shayovitz V, Masarwa R, Averbuch D. Gram-negative bacteremia in children with hematologic malignancies and following hematopoietic stem cell transplantation: epidemiology, resistance, and outcome. J Pediatr Hematol Oncol. 2019;41(8):e493–e8. doi:10.1097/MPH.000000000000155631318820
   PubMed Web of Science ®Google Scholar
• Conn JR, Catchpoole EM, Runnegar N, Mapp SJ, Markey KA. Low rates of antibiotic resistance and infectious mortality in a cohort of high-risk hematology patients: a single center, retrospective analysis of blood stream infection. PLoS One. 2017;12(5):e0178059. doi:10.1371/journal.pone.017805928542412
   PubMed Web of Science ®Google Scholar
• Babu KG, Lokanatha D, Lakshmaiah KC, et al. Bloodstream infections in febrile neutropenic patients at a tertiary cancer institute in South India: a timeline of clinical and microbial trends through the years. Indian J Med Paediatr Oncol. 2016;37(3):174–182. doi:10.4103/0971-5851.19035227688611
   PubMedGoogle Scholar
• Lakshmaiah KC, Malabagi AS, Govindbabu SR, Sinha M, Jayashree RS. Febrile neutropenia in hematological malignancies: clinical and microbiological profile and outcome in high risk patients. J Lab Physicians. 2015;7(2):116–120. doi:10.4103/0974-2727.16312626417163
   PubMedGoogle Scholar
• Micozzi A, Gentile G, Minotti C, et al. Carbapenem-resistant Klebsiella pneumoniae in high-risk haematological patients: factors favouring spread, risk factors and outcome of carbapenem-resistant Klebsiella pneumoniae bacteremias. BMC Infect Dis. 2017;17(1):203. doi:10.1186/s12879-017-2297-928283020
   PubMed Web of Science ®Google Scholar
• Reddy R, Pathania S, Kapil A, Bakhshi S. Review of spectrum and sensitivity of bacterial bloodstream isolates in children with malignancy: a retrospective analysis from a single center. Indian J Cancer. 2014;51(4):425–427. doi:10.4103/0019-509X.17536326842147
   PubMed Web of Science ®Google Scholar
• Escrihuela-Vidal F, Laporte J, Albasanz-Puig A, Gudiol C. Update on the management of febrile neutropenia in hematologic patients. Rev Esp Quimioter. 2019;32(Suppl 2):55–58.
   Google Scholar
• CADTH Rapid Response Reports. Carbapenems for Multi-Drug Resistant Infections: A Review of Guidelines. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health Copyright (c) 2016 Canadian Agency for Drugs and Technologies in Health; 2016.
   Google Scholar
• Torfoss D, Hoiby EA, Holte H, Kvaloy S. The Norwegian experience with penicillin G plus an aminoglycoside as initial empiric therapy in febrile neutropenia; a review. Acta Oncol. 2012;51(4):433–440. doi:10.3109/0284186X.2011.63393122175253
   PubMed Web of Science ®Google Scholar
• Gajdacs M. The concept of an ideal antibiotic: implications for drug design. Molecules. 2019;24:5. doi:10.3390/molecules24050892
   Web of Science ®Google Scholar
• Robinson PD, Lehrnbecher T, Phillips R, Dupuis LL, Sung L. Strategies for empiric management of pediatric fever and neutropenia in patients with cancer and hematopoietic stem-cell transplantation recipients: a systematic review of randomized trials. J Clin Oncol. 2016;34(17):2054–2060. doi:10.1200/JCO.2015.65.859127022114
   PubMed Web of Science ®Google Scholar
• Sezgin G, Acipayam C, Ozkan A, Bayram I, Tanyeli A. Meropenem versus piperacillin-tazobactam as empiric therapy for febrile neutropenia in pediatric oncology patients. Asian Pac J Cancer Prev. 2014;15(11):4549–4553. doi:10.7314/APJCP.2014.15.11.454924969883
   PubMedGoogle Scholar
• Haeusler GM, Sung L, Ammann RA, Phillips B. Management of fever and neutropenia in paediatric cancer patients: room for improvement? Curr Opin Infect Dis. 2015;28(6):532–538. doi:10.1097/QCO.000000000000020826381997
   PubMed Web of Science ®Google Scholar